{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:06:16Z","timestamp":1779318376701,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Hyperglyk\u00e4mie ist wesentlich an der Entstehung der Folgeerkrankungen bei Menschen mit Diabetes mellitus Typ\u00a02 beteiligt. W\u00e4hrend Lebensstilma\u00dfnahmen die Eckpfeiler jeder Diabetestherapie bleiben, ben\u00f6tigen die meisten Menschen mit Typ-2-Diabetes im Verlauf eine medikament\u00f6se Therapie. Bei der Definition individueller Behandlungsziele stellen die Therapiesicherheit, die Effektivit\u00e4t sowie substanzspezifische, organprotektive Effekte der Therapie die wichtigsten Faktoren dar. Diese nationale Leitlinie fasst die Evidenz aus der aktuellen Datenlage f\u00fcr die klinische Praxis zusammen.<\/jats:p>","DOI":"10.1007\/s00508-026-02716-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:01Z","timestamp":1779315361000},"page":"87-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antihyperglyk\u00e4mische Therapie bei Diabetes mellitus Typ\u00a02 (Update 2026)","Antihyperglycemic treatment of type\u00a02 diabetes mellitus (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Martin","family":"Clodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidemarie","family":"Abrahamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Br\u00e4uer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadriye","family":"Aydinkoc-Tuzcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Brath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Feder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fr\u00fchwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"F\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Fr\u00f6hlich-Reiterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Harreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"H\u00f6llerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Hoppichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joakim","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Kietaibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Lechleitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Leutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Parzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Pucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Rami-Merhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gersina","family":"Rega-Kaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Ress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph H.","family":"Saely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schelkshorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Stechemesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Steinmaurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stulnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tauschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlies","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Vonbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Weitgasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Winhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Zlamal-Fortunat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"5","key":"2716_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jacc.2021.05.004","volume":"78","author":"MC Honigberg","year":"2021","unstructured":"Honigberg\u00a0MC, et\u00a0al. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. J\u00a0Am Coll Cardiol. 2021;78(5):453\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2716_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff\u00a0AM, et\u00a0al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"10","key":"2716_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, et\u00a0al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"2716_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani\u00a0MA, et\u00a0al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015;17(3):268\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"10300","key":"2716_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik\u00a0B, et\u00a0al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"24","key":"2716_CR6","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls\u00a0SJ, et\u00a0al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409\u201320.","journal-title":"N Engl J Med"},{"issue":"9131","key":"2716_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type\u00a02 diabetes (UKPDS\u00a033). Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"issue":"15","key":"2716_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman\u00a0RR, et\u00a0al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"24","key":"2716_CR9","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"AC Group","year":"2008","unstructured":"Group\u00a0AC, et\u00a0al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"24","key":"2716_CR10","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study, G","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study, G, et\u00a0al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"2","key":"2716_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth\u00a0W, et\u00a0al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"34","key":"2716_CR12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini\u00a0E, DeFronzo\u00a0RA. Impact of glucose-lowering drugs on cardiovascular disease in type\u00a02 diabetes. Eur Heart J. 2015;36(34):2288\u201396.","journal-title":"Eur Heart J"},{"issue":"22","key":"2716_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, et\u00a0al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2716_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2716_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et\u00a0al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10489","key":"2716_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca\u00a0MP, et\u00a0al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393.","journal-title":"Lancet"},{"issue":"20","key":"2716_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire\u00a0DK, et\u00a0al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"9","key":"2716_CR18","first-page":"891","volume":"376","author":"SP Marso","year":"2017","unstructured":"Marso\u00a0SP, Holst\u00a0AG, Vilsboll\u00a0T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2017;376(9):891\u20132.","journal-title":"N Engl J Med"},{"issue":"9493","key":"2716_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy\u00a0JA, et\u00a0al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"17","key":"2716_CR20","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","volume":"49","author":"E Erdmann","year":"2007","unstructured":"Erdmann\u00a0E, et\u00a0al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J\u00a0Am Coll Cardiol. 2007;49(17):1772\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2716_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox\u00a0R, et\u00a0al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865\u201373.","journal-title":"Stroke"},{"issue":"4","key":"2716_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"OT Investigators","year":"2012","unstructured":"Investigators\u00a0OT, et\u00a0al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319\u201328.","journal-title":"N Engl J Med"},{"issue":"20","key":"2716_CR23","first-page":"1995","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso\u00a0SP, Buse\u00a0JB. Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(20):1995\u20136.","journal-title":"N Engl J Med"},{"issue":"21","key":"2716_CR24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, et\u00a0al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2716_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, et\u00a0al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"key":"2716_CR26","unstructured":"Solomon, S.D., et\u00a0al., Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med, 2022."},{"issue":"12","key":"2716_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, et\u00a0al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"2716_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer\u00a0M, et\u00a0al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"15","key":"2716_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, et\u00a0al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"2716_CR30","unstructured":"Group, E.-K.C., et\u00a0al., Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2022."},{"issue":"2","key":"2716_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, et\u00a0al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"21","key":"2716_CR32","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal\u00a0AJ, et\u00a0al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"2716_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba\u00a0R, et\u00a0al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"key":"2716_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin\u00a0J, et\u00a0al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735.","journal-title":"BMJ"},{"issue":"Suppl 10","key":"2716_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00508-025-02617-4","volume":"137","author":"M Mandorfer","year":"2025","unstructured":"Mandorfer\u00a0M, et\u00a0al. Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease : Austrian Society of Gastroenterology and Hepatology (OGGH), Austrian Society of Diabetology (ODG), Austrian Society of Obesity (OAG). Wien Klin Wochenschr. 2025;137(Suppl 10):307\u201319.","journal-title":"Wien Klin Wochenschr"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02716-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02716-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:03Z","timestamp":1779315363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02716-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":35,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02716-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Clodi gibt folgende Interessenkonflikte an: Vortr\u00e4ge, Studien und Beratung f\u00fcr Novo Nordisk, Elli Lilly, Boehringer Ingelheim, AstraZeneca, Novartis, Daiichi Sankyo, Amgen, W\u00f6rwag, Sanofi, Amarin, Roche, Bayer. H.\u00a0Abrahamian gibt folgende Interessenkonflikte f\u00fcr die letzten 3\u00a0Jahre an: Kongressunterst\u00fctzung durch AstraZeneca und Eli Lilly. F.\u00a0Aberer gibt folgende Offenlegungen an: erhielt Vortragshonorare von Sanofi-Aventis, Novo Nordisk, AMGEN und Eli Lilly und war Mitglied in Advisory Boards von Bayer, Eli Lilly und Novo Nordisk. A.\u00a0Br\u00e4uer erhielt Einladungen zu Kongressen, Honorare f\u00fcr Beratungs- oder Vortragst\u00e4tigkeiten bzw. Unterst\u00fctzungen f\u00fcr Fortbildungsveranstaltungen: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi-Aventis. K.\u00a0Aydinkoc-Tuzcu hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer Health Care, Bristol Myers Squibb, Germania Pharmazeutika, GlaxoSmithKline Pharma, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Takeda. Zus\u00e4tzlich gibt K.\u00a0Aydinkoc-Tuzcu an, dass f\u00fcr sie pers\u00f6nlich kein Interessenkonflikt vorliegt. H.\u00a0Brath hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Vortrags- oder Beratungshonorare oder Kongressunterst\u00fctzungen erhalten: Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Novo Nordisk, Roche, Sandoz, Sanofi, Servier, W\u00f6rwag. J.\u00a0Brix hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk. P.\u00a0Fasching gibt folgende Interessenkonflikte (f\u00fcr die letzten 3\u00a0Jahre) an: Honorare f\u00fcr Vortr\u00e4ge, Teilnahme an Advisory Boards und wissenschaftliches Consulting von AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi und Boehringer Ingelheim, sowie Kongressunterst\u00fctzung von Boehringer Ingelheim und Novo Nordisk und Teilnahme als Primary Investigator (PI) an klinischen Studien von Eli Lilly und Novo Nordisk. A.\u00a0Feder erhielt Vortragshonorare und\/oder Honorare f\u00fcr Beratungst\u00e4tigkeit von Eli Lilly, AstraZeneca und Bayer. L.\u00a0Fr\u00fchwald hat Vortragshonorare und \u00dcbernahme von Kongressgeb\u00fchren erhalten von E.\u00a0Lilly, Sanofi, Boehringer Ingelheim, Novo Nordisk, Abbott. E.\u00a0Fr\u00f6hlich-Reiterer gibt folgende Offenlegungen an: Forschungsunterst\u00fctzung und Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von Sanofi, E.\u00a0Lilly, Medtronic, Merck, Sandoz. J.\u00a0Harreiter hat von folgenden Unternehmen Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Ultragenyx. S.\u00a0Hofer hat in den letzten 36\u00a0Monaten von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: E.\u00a0Lilly, Sanofi und Ypsomed. F.\u00a0H\u00f6llerl hat von AstraZeneca Honorare f\u00fcr Vortragst\u00e4tigkeiten erhalten. J.\u00a0Huber hat von folgenden Unternehmen Fortbildungsunterst\u00fctzung und\/oder Honorare f\u00fcr Vortr\u00e4ge und Beratung erhalten: Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis, Merck Sharp & Dohme, Daiichi Sankyo, Viatris. Zus\u00e4tzlich gibt J.\u00a0Huber an, dass f\u00fcr ihn pers\u00f6nlich kein Interessenkonflikt vorliegt. S.\u00a0Kaser hat Vortragshonorare bzw. Beraterhonorare erhalten von Boehringer Ingelheim, Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, Amarin. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: B\u00f6hringer Ingelheim, Eli Lilly, Merck Sharp\u00a0&\u00a0Dohme, Novartis, Novo Nordisk, Roche, Sanofi-Aventis, Amgen. A.\u00a0Kietaibl gibt folgende Offenlegungen an: Honorare von Sanofi-Aventis GmbH und Roche Diabetes Care Austria GmbH erhalten. Kongressunterst\u00fctzung durch Novo Nordisk, Eli Lilly GmbH, Boehringer Ingelheim und \u00d6DG. G.\u00a0K\u00f6hler gibt folgende Interessenkonflikte an: Honorare von Amgen, Eli Lilly, Bayer, B\u00f6hringer Ingelheim, Daiichi Sankyo, Dexcom, Novartis, Novo Nordisk, Sanofi-Aventis GmbH und Roche Diabetes Care erhalten. S.E.\u00a0Hofer gibt folgende Interessenkonflikte (f\u00fcr die letzten 3\u00a0Jahre) an: Honorare f\u00fcr Vortr\u00e4ge und Teilnahme an Advisory Boards erhalten von Sanofi, E.\u00a0Lilly, Ypsomed. M.\u00a0Leutner hat von folgenden Unternehmen, die auch tlw. f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Sobi, Novartis, Novo Nordisk. B.\u00a0Ludvik gibt folgende Interessenkonflikte an: Honorare f\u00fcr Advisory Boards, Vortr\u00e4ge und Forschungsunterst\u00fctzung von: Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk. J.K.\u00a0Mader gibt folgende Interessenkonflikte an: Advisory Boards von Abbott Diabetes Care, Becton-Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Insulet, Medtronic, myLife, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem und Viatris; Honorare f\u00fcr Vortragst\u00e4tigkeit: A.\u00a0Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtrust, MSD, Novo Nordisk A\/S, Roche Diabetes Care, Sanofi, Viatris und Ypsomed. Gesellschafterin: decide Clinical Software GmbH und elyte Diagnostics. V.\u00a0Parzer hat Honorare f\u00fcr Vortragst\u00e4tigkeit\/Kongressunterst\u00fctzung von Eli Lilly und Novo Nordisk erhalten. B.\u00a0Paulweber hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Pfizer, Sanofi und Sobi. B.\u00a0Rami-Merhar hat in den letzten 36\u00a0Monaten von folgenden Firmen Honorare\/Forschungsgelder erhalten: Eli Lilly, Medtronic, Insulet, Abbott, Sanofi. G.\u00a0Rega-Kaun gibt folgende Interessenkonflikte (f\u00fcr die letzten 3\u00a0Jahre) an: Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge und Beratung: Amgen, Bayer Austria, Boehringer, Daiichi Sankyo, Eli Lilly, Novartis, Novo Nordisk, Sanofi, Ultragenyx und Viatris. Sowie Kongressunterst\u00fctzung von Eli Lilly, Novartis, Novo Nordisk und Ultragenyx. M.\u00a0Resl hat von folgenden Firmen Honorare und Forschungsgelder erhalten: Eli Lilly, Abbott, Boehringer Ingelheim, Roche, Bayer. M.\u00a0Riedl hat von Boehringer Ingelheim und Novo Nordisk Honorare und Forschungsgelder erhalten. M.\u00a0Roden gibt folgende Interessenkonflikte an: Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge und wissenschaftliche Beratung von AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Madrigal, Merck-MSD, Novo Nordisk, Synlab und Target RWE. M.\u00a0Roden f\u00fchrt \u201einvestigator-initiated studies\u201c mit Unterst\u00fctzung von Boehringer Ingelheim, Novo Nordisk und Sanofi und das Deutsche Diabetes Zentrum (DDZ) durch. C.H.\u00a0Saely hat Forschungsf\u00f6rderungen bzw. Sprecher- und Beraterhonorare von AstraZeneca, B\u00f6hringer Ingelheim, Lilly, Merck, MSD, Mylan, Novartis, Sanofi-Aventis, Viatris erhalten. C.\u00a0Schelkshorn hat Sprecher- und Beraterhonorare sowie Forschungsf\u00f6rderungen von Novo Nordisk, Boehringer Ingelheim, Sanofi, Abbott Diabetes, Lilly, Dexcom, Ypsomed, Roche erhalten. H.\u00a0Sourij hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi, Sobi. L.\u00a0Stechemesser hat f\u00fcr Vortragst\u00e4tigkeit und Forschungszusammenarbeit mit Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Daiichi Sankyo, Dexcom, Eli Lilly, Medtronic, Mylan, Novartis, Novo Nordisk, Roche Diabetes Care, Sanofi-Aventis Honorare erhalten. H.\u00a0Stingl hat von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und\/oder Beratert\u00e4tigkeit bzw. Fortbildungsunterst\u00fctzung erhalten: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi-Aventis, Viatris. T.\u00a0Stulnig hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: 89bio, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi. M.\u00a0Tauschmann war Mitglied von Advisory Boards f\u00fcr Sanofi und Abbott, erhielt Vortragshonorare von Eli Lilly, Medtronic, Sanofi und Ypsomed und Unterst\u00fctzung bei Konferenzteilnahme durch die KelCon GmbH. H.\u00a0Toplak hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge und Forschungsunterst\u00fctzungen erhalten: Vortr\u00e4ge f\u00fcr B\u00f6hringer Ingelheim und Novo Nordisk sowie Forschungsunterst\u00fctzung; klinische Studien f\u00fcr Boehringer Ingelheim und Novo Nordisk. G.\u00a0Treiber gibt folgende Interessenkonflikte an: Honorare f\u00fcr Vortr\u00e4ge und Reisekostenunterst\u00fctzung f\u00fcr Kongressteilnahme erhalten von Medtronic AT, Sanofi, E.\u00a0Lilly, Novo Nordisk, Bayer Austria, \u00d6DG, \u00d6sterreichische Akademie der \u00c4rzte. A.\u00a0Vonbank gibt folgende Interessenkonflikte an: Fortbildungsunterst\u00fctzungen bzw. Honorare f\u00fcr Forschungst\u00e4tigkeit, Beratungst\u00e4tigkeit oder Vortr\u00e4ge: Eli Lilly, Boehringer Ingelheim, Amarin, Daiichi Sankyo, Novo Nordisk, Sanofi-Aventis, AstraZeneca, Amgen, Bayer, LKH Feldkirch. T.C.\u00a0Wascher gibt folgende Interessenkonflikte an: Forschungsunterst\u00fctzungen und\/oder Honorare von Amgen, AstraZeneca, Bayer Austria, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Daiichi Sankyo. R.\u00a0Weitgasser hat f\u00fcr Vortragst\u00e4tigkeit und Forschungszusammenarbeit mit Spar, Eli Lilly, Novo Nordisk, Daiichi Sankyo und Boehringer Ingelheim Honorare erhalten. Y.\u00a0Winhofer gibt folgende Interessenkonflikte (f\u00fcr die letzten 3\u00a0Jahre) an: Honorare f\u00fcr Vortr\u00e4ge, Teilnahme an Advisory Boards, wissenschaftliches Consulting und Kongressunterst\u00fctzung von folgenden Unternehmen: Abbott, Amarin, AstraZeneca, Bayer Austria, Boehringer Ingelheim Daiichi Sankyo, Dexcom, Eli Lilly, MSD, Novartis, Novo Nordisk, Roche Diabetes Care, Sanofi-Aventis. S.\u00a0Zlamal-Fortunat hat in den letzten 36\u00a0Monaten Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von Novo Nordisk, Sanofi, Johnson\u00a0&\u00a0Johnson, Bayer, Amarin, AstraZeneca, Boehringer Ingelheim, Medtronic, Daiichi Sankyo und Novartis erhalten. H.\u00a0Drexel, M.\u00a0Fritsch, B.\u00a0F\u00f6ger, C.\u00a0Francesconi, F.\u00a0Hoppichler, S.\u00a0Huber, M.\u00a0Lechleitner, T.\u00a0Pieber, R.\u00a0Prager, E.\u00a0Pucher, C.\u00a0Ress, G.\u00a0Schernthaner und Th.\u00a0Steinmaurer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}